Start for free

Natco Pharma Limited

NSE: NATCOPHARMHealthcare

Natco Pharma Limited Share Price & Analysis

₹828.65−1.15%Updated 4 Sept 2026, 03:30 pm IST
LTP
₹828.65−1.15%
Open
₹839.00
High
₹841.80
Low
₹826.70
Close
₹828.65
52W High
₹1227.00
52W Low
₹786.24
Volume
445K
Lot Size
1
Sector
Healthcare
Market Cap
₹15K Cr
Face Value
₹2
Mid CapNIFTY 500SMALLCAP 100Nifty Smallcap 250

Price Chart

Candle
Range

Fundamentals

P/E
13.00
Sector P/E
54.70
P/B
1.95
EPS
₹79.24
ROE
16.90%
ROCE
17.10%
D/E Ratio
0.08
Div Yield
0.60%
Book Value
₹515.00

Strengths

  • Strong return on equity (ROE 16.9%)
  • Efficient capital deployment (ROCE 17.1%)
  • Attractively valued vs sector (P/E 13x vs industry 54.7x)
  • Virtually debt-free
  • Near 52-week low — potential value zone (₹786)

Concerns

    Peer Comparison

    CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
    SUNPHARMA
    Sun Pharmaceutical Industries Limited
    ₹1,899
    		₹4.6L Cr36.15.461620.50.07
    DIVISLAB
    Divi's Laboratories Limited
    ₹9,100
    		₹2.4L Cr81.114.4216.5220.01
    TORNTPHARM
    Torrent Pharmaceuticals Limited
    ₹4,857
    		₹1.8L Cr82.819.5827.415.20.33
    APOLLOHOSP
    Apollo Hospitals Enterprise Limited
    ₹8,650
    		₹1.2L Cr59.113.1321.217.40.88
    CIPLA
    Cipla Limited
    ₹1,385
    		₹1.1L Cr31.33.2511.615.50.01
    ZYDUSLIFE
    Zydus Lifesciences Limited
    ₹1,120
    		₹1.1L Cr234.1621.221.10.38
    LAURUSLABS
    Laurus Labs Limited
    ₹1,840
    		₹99K Cr90.918.7418.317.80.46

    Showing 7 peers in the same sector · Sorted by market cap

    Shareholding Pattern

    NATCOPHARM · as of Mar 2026

    Promoters49.56%0.06pp
    FII17.49%0.45pp
    DII5.64%0.05pp
    Public27.30%0.42pp
    CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
    Promoters49.71%49.71%49.71%49.62%49.62%49.56%
    FII13.72%16.14%17.45%17.51%17.94%17.49%
    DII11.26%9.69%7.86%6.75%5.59%5.64%
    Public25.32%24.46%24.99%26.13%26.88%27.30%

    Corporate Events

    To consider Fund Raising

    Event8 Sept 2026

    Interim Dividend - Rs 1.50 Per Share

    Dividend19 Aug 2026

    To consider and approve the financial results for the period ended Jun 30, 2026 and declare interim dividend, if any for the FY 2026-27

    Dividend13 Aug 2026

    To consider Fund Raising

    Event13 Aug 2026

    Interim Dividend - Rs 1.50 Per Share

    Dividend17 Feb 2026

    Interim Dividend - Rs 1.50 Per Share

    Dividend19 Nov 2025

    Interim Dividend - Rs 2 Per Share

    Dividend18 Aug 2025

    Interim Dividend - Rs 1.50 Per Share

    Dividend17 Feb 2025

    Interim Dividend - Rs 1.50 Per Share

    Dividend26 Nov 2024

    Annual General Meeting

    AGM24 Sept 2024

    Latest News

    All news

    Natco Pharma declares interim dividend for FY26-27

    *Natco Pharma declares interim dividend for FY26-27.* The board approved a dividend payout, though the exact amount remains undisclosed. This follows the company’s routine dividend schedule. Interim dividends typically support investor sentiment but don’t alter fundamentals. 📊 *STOCKS:* $NATCOPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend

    NSE Filing14 Aug
    High Impact

    Natco Pharma announces board meeting outcomes

    *Natco Pharma announces board meeting outcomes*. The company disclosed the outcomes of its recent board meeting held on July 08, 2026. No major strategic decisions or financial announcements were revealed. The update is primarily procedural in nature with no immediate business impact. 📊 *STOCKS:* NATCOPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma

    NSE Filing8 Jul
    High Impact

    Natco Pharma invests in US biotech eGenesis Inc

    *Natco Pharma invests in US biotech eGenesis Inc.* The company announced a strategic investment in eGenesis, Inc., a Massachusetts-based biotech firm, to explore cutting-edge biopharma opportunities. This move aims to strengthen Natco’s global footprint in advanced therapeutics. Financial details were not disclosed. 📊 *STOCKS:* $NATCOPHARM | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Investment

    NSE Filing25 Aug
    Medium Impact

    Natco Pharma acquires additional 13.25% stake in Adcock Ingram

    *Natco Pharma acquires additional 13.25% stake in Adcock Ingram* — Natco Pharma has increased its holding in South Africa-based Adcock Ingram Holdings by acquiring an additional **13.25% stake**. This move strengthens its strategic footprint in the African pharmaceutical market. The acquisition enhances Natco’s control and potential revenue share in the joint venture. 📊 *STOCKS:* NATCOPHARM | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Acquisition

    NSE Filing14 Jul
    Medium Impact

    Natco Pharma sets dividend record date

    *Natco Pharma sets dividend record date*. The company has announced **20-Aug-2026** as the record date for dividend distribution. This follows its recent corporate filing with the NSE. Shareholders registered by the record date will be eligible for the dividend payout. 📊 *STOCKS:* $NATCOPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend

    NSE Filing14 Aug
    Low Impact

    Financials

    Quarterly Results

    MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    Revenue
    ₹739 Cr
    14.2%
    ₹647 Cr
    52.5%
    ₹1.4K Cr
    2.6%
    ₹1.3K Cr
    8.8%
    ₹1.2K Cr
    157.1%
    ₹475 Cr
    65.4%
    ₹1.4K Cr
    0.6%
    ₹1.4K Cr
    Op. Profit
    ₹128 Cr
    19.5%
    ₹159 Cr
    72.5%
    ₹579 Cr
    1.4%
    ₹571 Cr
    4.2%
    ₹548 Cr
    1305.1%
    ₹39 Cr
    95.1%
    ₹804 Cr
    0.1%
    ₹805 Cr
    OPM
    17.0%
    32.0%
    25.0%
    40.5%
    42.0%
    2.3%
    43.0%
    4.4%
    45.0%
    462.5%
    8.0%
    86.4%
    59.0%
    0.0%
    59.0%
    Net Profit
    ₹269 Cr
    78.1%
    ₹151 Cr
    70.8%
    ₹518 Cr
    7.9%
    ₹480 Cr
    18.2%
    ₹406 Cr
    207.6%
    ₹132 Cr
    80.5%
    ₹676 Cr
    1.2%
    ₹668 Cr
    EPS (₹)
    14.96
    76.8%
    8.46
    70.8%
    28.94
    7.8%
    26.84
    18.2%
    22.7
    205.5%
    7.43
    80.3%
    37.81
    1.3%
    37.32

    Values in ₹ Cr · Source: Screener.in

    Annual Profit & Loss

    MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Revenue
    ₹4.1K Cr
    7.9%
    ₹4.4K Cr
    10.8%
    ₹4.0K Cr
    47.7%
    ₹2.7K Cr
    39.2%
    ₹1.9K Cr
    5.2%
    ₹2.1K Cr
    7.2%
    ₹1.9K Cr
    8.5%
    ₹2.1K Cr
    4.2%
    ₹2.2K Cr
    8.2%
    ₹2.0K Cr
    Expenses
    ₹2.6K Cr
    18.3%
    ₹2.2K Cr
    0.5%
    ₹2.2K Cr
    26.7%
    ₹1.8K Cr
    5.4%
    ₹1.7K Cr
    16.3%
    ₹1.4K Cr
    8.6%
    ₹1.3K Cr
    2.5%
    ₹1.3K Cr
    3.5%
    ₹1.3K Cr
    6.1%
    ₹1.3K Cr
    Op. Profit
    ₹1.4K Cr
    34.6%
    ₹2.2K Cr
    25.2%
    ₹1.8K Cr
    87.4%
    ₹936 Cr
    254.5%
    ₹264 Cr
    56.4%
    ₹606 Cr
    3.9%
    ₹583 Cr
    26.7%
    ₹795 Cr
    14.3%
    ₹928 Cr
    35.9%
    ₹683 Cr
    OPM
    35.0%
    30.0%
    50.0%
    13.6%
    44.0%
    25.7%
    35.0%
    150.0%
    14.0%
    53.3%
    30.0%
    0.0%
    30.0%
    21.1%
    38.0%
    9.5%
    42.0%
    23.5%
    34.0%
    Other Income
    ₹298 Cr
    15.8%
    ₹354 Cr
    181.0%
    ₹126 Cr
    20.0%
    ₹105 Cr
    6.1%
    ₹99 Cr
    4.8%
    ₹104 Cr
    2.8%
    ₹107 Cr
    17.7%
    ₹130 Cr
    225.0%
    ₹40 Cr
    185.7%
    ₹14 Cr
    Interest
    ₹37 Cr
    54.2%
    ₹24 Cr
    26.3%
    ₹19 Cr
    35.7%
    ₹14 Cr
    22.2%
    ₹18 Cr
    38.5%
    ₹13 Cr
    40.9%
    ₹22 Cr
    15.8%
    ₹19 Cr
    26.7%
    ₹15 Cr
    16.7%
    ₹18 Cr
    Depreciation
    ₹207 Cr
    11.9%
    ₹235 Cr
    25.7%
    ₹187 Cr
    14.0%
    ₹164 Cr
    14.7%
    ₹143 Cr
    22.2%
    ₹117 Cr
    17.0%
    ₹100 Cr
    23.5%
    ₹81 Cr
    22.7%
    ₹66 Cr
    22.2%
    ₹54 Cr
    PBT
    ₹1.5K Cr
    34.9%
    ₹2.3K Cr
    36.9%
    ₹1.7K Cr
    94.2%
    ₹862 Cr
    326.7%
    ₹202 Cr
    65.2%
    ₹580 Cr
    1.9%
    ₹569 Cr
    31.0%
    ₹825 Cr
    7.0%
    ₹887 Cr
    42.1%
    ₹624 Cr
    Tax %
    8.0%
    55.6%
    18.0%
    5.9%
    17.0%
    0.0%
    17.0%
    6.3%
    16.0%
    33.3%
    24.0%
    26.3%
    19.0%
    13.6%
    22.0%
    0.0%
    22.0%
    0.0%
    22.0%
    Net Profit
    ₹1.4K Cr
    24.7%
    ₹1.9K Cr
    35.7%
    ₹1.4K Cr
    94.1%
    ₹715 Cr
    320.6%
    ₹170 Cr
    61.5%
    ₹442 Cr
    3.5%
    ₹458 Cr
    28.7%
    ₹642 Cr
    7.6%
    ₹695 Cr
    43.3%
    ₹485 Cr
    EPS (₹)
    79.2
    24.8%
    105.26
    35.8%
    77.51
    97.8%
    39.18
    320.8%
    9.31
    61.5%
    24.18
    4.5%
    25.31
    28.2%
    35.24
    6.6%
    37.74
    35.4%
    27.88
    Div Payout
    6.0%
    0.0%
    6.0%
    50.0%
    12.0%
    14.3%
    14.0%
    70.8%
    48.0%
    118.2%
    22.0%
    18.5%
    27.0%
    50.0%
    18.0%
    18.2%
    22.0%
    8.3%
    24.0%

    Values in ₹ Cr · Source: Screener.in

    Balance Sheet

    ItemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Liabilities
    Equity Capital
    ₹36 Cr
    0.0%
    ₹36 Cr
    0.0%
    ₹36 Cr
    0.0%
    ₹36 Cr
    0.0%
    ₹36 Cr
    0.0%
    ₹36 Cr
    0.0%
    ₹36 Cr
    0.0%
    ₹36 Cr
    2.7%
    ₹37 Cr
    5.7%
    ₹35 Cr
    Reserves
    ₹9.2K Cr
    21.3%
    ₹7.6K Cr
    30.2%
    ₹5.8K Cr
    20.3%
    ₹4.8K Cr
    14.4%
    ₹4.2K Cr
    3.5%
    ₹4.1K Cr
    9.3%
    ₹3.7K Cr
    8.3%
    ₹3.5K Cr
    13.7%
    ₹3.0K Cr
    88.0%
    ₹1.6K Cr
    Borrowings
    ₹714 Cr
    155.9%
    ₹279 Cr
    24.8%
    ₹371 Cr
    122.2%
    ₹167 Cr
    59.9%
    ₹416 Cr
    55.2%
    ₹268 Cr
    15.2%
    ₹316 Cr
    18.1%
    ₹386 Cr
    123.1%
    ₹173 Cr
    22.1%
    ₹222 Cr
    Other Liabilities
    ₹1.1K Cr
    53.1%
    ₹744 Cr
    9.1%
    ₹682 Cr
    10.5%
    ₹617 Cr
    43.5%
    ₹430 Cr
    6.7%
    ₹403 Cr
    19.1%
    ₹498 Cr
    16.4%
    ₹428 Cr
    8.9%
    ₹470 Cr
    5.4%
    ₹446 Cr
    Total Liabilities
    ₹11.1K Cr
    28.3%
    ₹8.6K Cr
    25.0%
    ₹6.9K Cr
    22.1%
    ₹5.7K Cr
    10.7%
    ₹5.1K Cr
    6.6%
    ₹4.8K Cr
    4.4%
    ₹4.6K Cr
    6.6%
    ₹4.3K Cr
    15.8%
    ₹3.7K Cr
    60.3%
    ₹2.3K Cr
    Assets
    Fixed Assets
    ₹2.8K Cr
    3.9%
    ₹2.7K Cr
    8.3%
    ₹2.5K Cr
    2.6%
    ₹2.4K Cr
    5.0%
    ₹2.3K Cr
    14.3%
    ₹2.0K Cr
    27.7%
    ₹1.6K Cr
    29.1%
    ₹1.2K Cr
    20.4%
    ₹1.0K Cr
    22.3%
    ₹833 Cr
    CWIP
    ₹294 Cr
    30.7%
    ₹225 Cr
    64.2%
    ₹137 Cr
    114.1%
    ₹64 Cr
    50.8%
    ₹130 Cr
    41.7%
    ₹223 Cr
    56.9%
    ₹518 Cr
    18.8%
    ₹638 Cr
    32.9%
    ₹480 Cr
    42.9%
    ₹336 Cr
    Investments
    ₹3.1K Cr
    559.7%
    ₹474 Cr
    12.1%
    ₹539 Cr
    37.5%
    ₹392 Cr
    27.3%
    ₹308 Cr
    1.3%
    ₹304 Cr
    171.4%
    ₹112 Cr
    33.7%
    ₹169 Cr
    122.4%
    ₹76 Cr
    137.5%
    ₹32 Cr
    Other Assets
    ₹4.8K Cr
    7.3%
    ₹5.2K Cr
    40.0%
    ₹3.7K Cr
    34.8%
    ₹2.8K Cr
    17.5%
    ₹2.4K Cr
    5.3%
    ₹2.2K Cr
    5.5%
    ₹2.4K Cr
    4.5%
    ₹2.3K Cr
    6.1%
    ₹2.1K Cr
    91.8%
    ₹1.1K Cr
    Total Assets
    ₹11.1K Cr
    28.3%
    ₹8.6K Cr
    25.0%
    ₹6.9K Cr
    22.1%
    ₹5.7K Cr
    10.7%
    ₹5.1K Cr
    6.6%
    ₹4.8K Cr
    4.4%
    ₹4.6K Cr
    6.6%
    ₹4.3K Cr
    15.8%
    ₹3.7K Cr
    60.3%
    ₹2.3K Cr

    Values in ₹ Cr · Source: Screener.in

    Cash Flow Statement

    ItemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Operating CF
    ₹1.8K Cr
    4.2%
    ₹1.7K Cr
    40.0%
    ₹1.2K Cr
    42.8%
    ₹849 Cr
    1745.7%
    ₹46 Cr
    84.6%
    ₹299 Cr
    28.3%
    ₹417 Cr
    37.7%
    ₹669 Cr
    44.2%
    ₹464 Cr
    34.1%
    ₹346 Cr
    Investing CF
    ₹-2.1K Cr
    45.0%
    ₹-1.4K Cr
    40.0%
    ₹-1.0K Cr
    120.6%
    ₹-465 Cr
    11725.0%
    ₹4 Cr
    103.7%
    ₹-107 Cr
    38.9%
    ₹-175 Cr
    71.4%
    ₹-611 Cr
    45.3%
    ₹-1.1K Cr
    273.2%
    ₹-299 Cr
    Financing CF
    ₹298 Cr
    241.2%
    ₹-211 Cr
    14.6%
    ₹-247 Cr
    32.0%
    ₹-363 Cr
    1137.1%
    ₹35 Cr
    118.8%
    ₹-186 Cr
    25.9%
    ₹-251 Cr
    392.2%
    ₹-51 Cr
    107.8%
    ₹651 Cr
    1456.3%
    ₹-48 Cr
    Net Cash Flow
    ₹-16 Cr
    132.0%
    ₹50 Cr
    180.6%
    ₹-62 Cr
    395.2%
    ₹21 Cr
    75.3%
    ₹85 Cr
    1316.7%
    ₹6 Cr
    175.0%
    ₹-8 Cr
    214.3%
    ₹7 Cr
    450.0%
    ₹-2 Cr
    100.0%
    ₹-1 Cr
    Free Cash Flow
    ₹1.4K Cr
    6.1%
    ₹1.3K Cr
    52.0%
    ₹855 Cr
    26.9%
    ₹674 Cr
    574.6%
    ₹-142 Cr
    254.3%
    ₹92 Cr
    13.6%
    ₹81 Cr
    64.0%
    ₹225 Cr
    294.7%
    ₹57 Cr
    13.6%
    ₹66 Cr

    Values in ₹ Cr · Source: Screener.in

    Key Ratios History

    MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Debtor Days
    79d
    23.3%
    103d
    5.5%
    109d
    5.2%
    115d
    0.9%
    116d
    58.9%
    73d
    30.5%
    105d
    19.3%
    88d
    17.0%
    106d
    23.3%
    86d
    Inventory Days
    480d
    18.5%
    405d
    13.4%
    357d
    17.4%
    432d
    12.9%
    496d
    13.0%
    570d
    6.7%
    534d
    2.0%
    545d
    40.1%
    389d
    82.6%
    213d
    Days Payable
    216d
    49.0%
    145d
    20.8%
    120d
    21.6%
    153d
    45.7%
    105d
    1.0%
    104d
    57.4%
    244d
    8.9%
    224d
    6.3%
    239d
    49.4%
    160d
    Cash Conv. Cycle
    343d
    5.2%
    362d
    4.9%
    345d
    12.4%
    394d
    22.3%
    507d
    5.9%
    539d
    36.5%
    395d
    3.7%
    410d
    59.5%
    257d
    86.2%
    138d
    Working Capital Days
    163d
    7.9%
    151d
    0.0%
    151d
    23.7%
    198d
    22.7%
    256d
    4.1%
    246d
    16.6%
    295d
    42.5%
    207d
    3.7%
    215d
    202.8%
    71d
    ROCE
    17.0%
    48.5%
    33.0%
    10.0%
    30.0%
    66.7%
    18.0%
    350.0%
    4.0%
    69.2%
    13.0%
    7.1%
    14.0%
    39.1%
    23.0%
    34.3%
    35.0%
    10.3%
    39.0%

    Source: Screener.in · Lower days = better efficiency

    Related Analysis

    Same Sector

    ALKEMAlkem Laboratories LimitedNeutralAPOLLOHOSPApollo Hospitals Enterprise LimitedNeutralAUROPHARMAAurobindo Pharma LimitedNeutralBIOCONBiocon LimitedNeutralCIPLACipla LimitedNeutral

    Frequently Asked Questions

    What is Natco Pharma Limited share price today?
    Natco Pharma Limited (NATCOPHARM) is currently trading at ₹828.65 on NSE, down 1.15% as of the last market session. Prices update daily after market close on MarketNetra.
    Is Natco Pharma Limited available in F&O (Futures & Options)?
    Yes, Natco Pharma Limited (NATCOPHARM) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
    What is Natco Pharma Limited 52-week high and low?
    Natco Pharma Limited's 52-week high is ₹1,227 and the 52-week low is ₹786.24. The current price of ₹828.65 is 32.5% below the 52W high.
    What is Natco Pharma Limited P/E ratio?
    Natco Pharma Limited's current P/E ratio is 13. This indicates the market is paying ₹13 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
    How to trade Natco Pharma Limited options?
    Natco Pharma Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade NATCOPHARM options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.